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Abstract
Kidney transplantation remains the optimal treatment option for patients with endstage renal disease. We aim to improve organ preservation during transplantation by reducing
damage from ischemia reperfusion injury (IRI) using existing clinically approved drugs. In
this study, we developed and characterized an in vitro model that mimics the conditions of
IRI in kidney transplant as a tool to screen and study the therapeutic effect of drugs in the
context of IRI. We recapitulated several key outcomes in IRI in our model, including the
induction of hypoxia, cell death, increased expression of damage markers (NGAL, HMBG-1)
and pro-inflammatory cytokines in a sterile environment (IL-6, TNF- α). Additionally, we
validated our model as a screening tool by testing select drugs for their ability to mitigate
IRI. Overall, this study provides the foundation for further research that can improve organ
preservation strategies, thereby increasing the quantity and quality of kidneys available for
transplant.
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Summary for Lay Audience
Over 40,000 Canadians suffer from kidney failure. Transplantation remains the best
treatment for these individuals, providing better quality of life and survival than dialysis.
However, the damage to organs during the transplant surgery, known as ischemia reperfusion
injury, remains a challenge to the success of kidney transplant. Ischemia refers to reduced
blood flow during organ retrieval and storage, where reperfusion is the restoration of blood
flow upon transplantation of the organ into the recipient. This injury causes cell death and
inflammation in the transplanted organ leading to poor function. Therapeutics that prevent
damage from this injury will be helpful in preserving the quality of transplanted organs and
allow them to function longer. Our group hopes to repurpose an existing drug in the context
of kidney transplantation, however a relevant model to test these drugs is required. In this
study, we have developed and characterized a human kidney cell model that accurately
encompasses the damage experienced by donor kidneys during transplantation. Additionally,
we have carried out preliminary drug testing to determine the usefulness of the model to
screen drugs. In future, this model will be used for a large-scale drug screen and to study
drugs for their ability to prevent kidney injury during the transplant process. Ultimately, we
hope to improve the quality of kidney a transplant patient receives.
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Chapter 1

1

Introduction

1.1 Current Challenges in Kidney Transplantation
End-stage renal disease (ESRD) represents a significant global health concern as it is
incurable and among the leading causes of death worldwide1. Globally, the incidence of
ESRD has been on the rise in recent years, a trend which is also evident in Canada. As of
2019, over 40,000 Canadians were reported to be living with ESRD, representing a 33%
increase since 20102. Consequently, every year the rate of Canadians receiving renal
replacement therapy due to kidney failure increases by ~1.6%, placing a significant
burden on the healthcare system2.
The two main types of renal replacement therapies are dialysis and kidney
transplantation. Kidney transplantation is the preferred treatment option as it offers more
favorable patient outcomes at reduced costs compared to dialysis3,4. Most importantly, as
reported by the Canadian Institute for Health Information, the 5-year survival of patients
who receive a kidney transplant is significantly higher at 85%, compared to 47% for
patients on dialysis (depending on type of dialysis and organ received)5. Additionally,
results from a systematic review by Tonelli et al., which examined the outcomes of 110
studies, found that kidney transplantation was associated with a reduced risk of mortality
and improved quality of life compared to dialysis6. Several studies have also indicated
that kidney transplantation is more cost effective than chronic dialysis7,8. For these
reasons and due to the increase in patients with ESRD, the number of kidney transplants
performed each year has been on the rise. For example, in Canada, there were 1,648
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kidney transplants performed in 2019, a 41% increase in the annual transplantation rate
from 2010, indicating an increased demand for transplantation5.

1.1.1

Transplantable Organ Shortage and Expanding the Donor
Pool

A limitation to kidney transplantation as a therapeutic approach is the shortage of
acceptable donor kidneys available for transplantation compared to the number of
patients with ESRD who require transplantation. As a result, the waitlist for kidney
transplantation is rapidly expanding. The Canadian Institute for Health Information
reported 3,261 patients waitlisted for a kidney transplant in 2019, which represents a
~37% increase from 20109. Additionally, in 2019, over 1,613 patients were left waiting
for a transplant. To address this growing supply and demand issue, organs from marginal
donors are being used more frequently10.
A main source of organs come from donation after cardiac death (DCD) donors.
Many transplant centers worldwide have adopted the use of DCD organs as an avenue to
increase the number of kidneys available for transplantation. For example, in 2019, over
30% of kidney transplants performed across Canada were from DCD donors compared to
22% in 2015, making DCD the fastest growing type of organ donation9,11. DCD organ
donation is defined as the donation of organs from patients who have died with cardiac
arrest. Unlike organs from living donation or donation after neurological death, DCD
kidneys undergo a 20-to-60-minute period of warm ischemia from the time the donor’s
heart stops beating until the organ is procured. The additional warm ischemic injury to
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the kidney while in the donor has been associated with an increased risk of poor graft
outcomes post-transplantation12.

1.1.2

Kidney Transplant Outcomes Using DCD Donors

While DCD organ donation can increase the number of organs available for
transplant, these organs are also more susceptible to damage during the transplantation
process and subsequently, exhibit poorer outcomes post-transplant. Most importantly,
kidneys from DCD donors have a 20% increased risk of delayed graft function compared
to organs from other donor types13.
Delayed graft function (DGF) is defined as the need for at least one session of
dialysis within the first week after transplantation14. Pathologically, DGF is a
manifestation of acute kidney injury in the early post-transplantation period strongly
associated with poor graft outcomes. A systematic review and meta-analysis of 33 studies
comparing recipient outcomes reported a 38% increased risk of acute allograft rejection
and a 41% increased risk of early graft loss in patients who experienced DGF compared
to those without15. As such, DGF remains a prevalent concern in the transplant
community and a threat to the long-term success of kidney transplantation.

1.2 Ischemia-Reperfusion Injury in Kidney Transplantation
The major mechanism that contributes to delayed graft function in kidney
transplant recipients is ischemia reperfusion injury (IRI). In DCD kidney transplantation,
ischemia refers to the cessation of blood flow that begins during donor death and organ
procurement and continues during organ storage and implantation into the recipient,
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where reperfusion refers to the re-establishment of blood flow upon implantation of the
organ into the recipient. The kidney experiences two types of ischemia during
transplantation: warm and cold ischemia. Warm ischemia occurs while the kidney is in
the body, while cold ischemia refers to the storage period once the kidney is procured and
prior to implantation. Warm ischemic periods are shorter, ranging from 20 to 60 minutes,
however, damage occurs more rapidly at higher temperatures with complete loss of ATP
and subsequent organ function observed after only 40 minutes16. Contrarily, organs can
tolerate several hours of cold ischemia without significant loss of function, however, the
combination with warm ischemia and damage from cold is detrimental to the organ17.
The kidney is the third most susceptible organ to ischemic injury, only behind the brain
and heart18. Therefore, the length and severity of IRI play a key role in determining the
quality of organ being transplanted12,19.

1.2.1

Pathobiology of Renal IRI

At the tissue level, ischemia is characterized by a decrease in oxygen and nutrient
delivery to cells. Due to the lack of oxygen, there is dysfunction of the electron transport
chain and cells switch from aerobic to anaerobic metabolism. In the kidney, the proximal
tubular epithelial cells are most sensitive to damage from ischemic injury due to their
increased metabolic demand and poor glycolytic capacity compared to distal tubular
segments20–22. The switch to anaerobic metabolism causes a decrease in ATP production
and creates an acidic environment from byproducts, such as lactic acid23. The shortage of
ATP leads to the dysfunction of membrane bound ATPases, such as the Na+/K+
ATPase24. ATP depletion also results in mislocalization of transporters and breakdown of
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tight junctions. As a result, there is an increase in intracellular Na+ which causes water to
enter the cells. Accumulation of metabolites and dephosphorylation of ATP contribute to
the hyperosmolarity of ischemic cells, further promoting the influx of water and causing
cells to swell, resulting in cellular edema25.
Depleted ATP levels also result in the accumulation of intracellular Ca2+, as it can no
longer be pumped out of the cell and its reuptake by the endoplasmic reticulum is
inhibited26,27. Calcium overload within the cell and mitochondria contributes to increased
mitochondrial permeability and the production of reactive oxygen species (ROS)28. Due
to the lack of oxygen present during ischemia, the formation of ROS is relatively
limited29. However, there is also a decrease in production of antioxidant enzymes which
inhibits the ability of the cell to deal with ROS upon reperfusion30,31.
During ischemia, a number of pathways are activated to help the cell respond to
hypoxic conditions. The principal defence mechanism of the cell in controlling the
response to hypoxia is the hypoxia-inducible factor 1 (HIF-1) pathway32–34. HIF-1 is a
heterodimeric transcription factor that controls the expression of hundreds of target
genes35. The two subunits of HIF-1 are: the HIF- 1α protein, which is an oxygen
regulated protein that is degraded under normal oxygen levels and HIF-1β, a
constitutively expressed beta subunit. During hypoxia, the enzymes that degrade HIF-1α
are inhibited, allowing it to accumulate and dimerize with the beta subunit. This in turn
leads to the transcription of genes with protective functions against hypoxia, such as
those involved in angiogenesis, glycolysis and tissue repair36,37.
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Upon re-establishment of renal blood flow, oxygen and nutrient levels increase within
the cell. This increase leads to the normalization of cellular pH, as waste products are
removed, and the cell resumes aerobic metabolism. Paradoxically, the re-establishment of
homeostatic conditions leads to further damage to the cell. The normalization of pH
activates cell damaging calcium-dependent proteases which accumulated during
ischemia32. Additionally, leaked electrons in the mitochondria from ischemic conditions
readily form ROS which cannot be eliminated by the impaired antioxidant system38.
ROS damage mitochondrial proteins and lipids which, paired with swelling from the
accumulation of intracellular Ca2+, contributes to the formation of the mitochondrial
permeability transition pore (mPTP)39,40. The opening of the mPTP releases cytochrome
C, succinate, and mitochondrial DNA into the cytosol, that act as mediators to initiate cell
death and inflammation41, which will be discussed in subsequent sections.

1.3 Consequences of Renal IRI
There are several consequences of IRI during kidney transplantation at the tissue
level that contribute to the poor clinical outcomes observed post-transplant. The main
drivers of damage are activation of cell death pathways, stimulation of innate immune
receptors and initiation of the inflammatory response.

1.3.1

Cell Death and Damage
During prolonged ischemia reperfusion injury, cell damage from ROS and

proteolytic enzymes can trigger the activation of cell death pathways42. There are several
forms of cell death observed during IRI in kidney transplantation. The following section
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presents a brief summary of the most relevant cell death pathways in kidney transplant:
necrosis, apoptosis, necroptosis and ferroptosis.
Necrosis
Necrosis is an uncontrolled form of cell death that is characterized by
mitochondrial dysfunction, lack of nuclear fragmentation, cellular swelling and eventual
rupture of surface membranes which leads to the release of intracellular components43.
As such, necrosis is considered to be pro-inflammatory as released cellular proteins and
DNA can act as damage-associated molecular patterns (DAMPs) to stimulate the innate
immune system and further propagate the inflammatory response44.
Apoptosis
In contrast to necrosis, apoptosis is a highly regulated and controlled cell death
process characterized by cell shrinkage, pyknosis of the nucleus, controlled degradation
of cellular components leading to membrane blebbing, and the formation of apoptotic
bodies45. Apoptosis can be initiated by either the intrinsic or extrinsic pathway. During
IRI, the intrinsic apoptosis pathway is initiated by the opening of mPTP, which is
regulated in part by members of the B-cell lymphoma 2 (Bcl-2) family, pro-apoptotic
proteins Bcl-2 associated X protein (Bax) and Bcl-2 homologous antagonist killer (Bak),
which increase mitochondrial membrane permeability46,47. This results in the release of
death molecules, including cytochrome C and ROS, into the cytosol48. These molecules
lead to the activation of caspase 9 and downstream caspases.
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The extrinsic pathway of apoptosis is also activated during renal IRI. This pathway
involves the binding of ligands to death receptors on the surface of cells leading to
caspase activation. The most well-characterized ligand-receptor interactions are tumour
necrosis factor alpha (TNF-α)/TNF receptor 1 and Fas ligand/Fas receptor49,50. Binding of
these ligands to their receptor triggers the activation of caspase 8 and 1051. Both the
intrinsic and extrinsic pathways of apoptosis end with the activation of effector caspases.
Effector caspases initiate the execution phase of apoptosis, which is marked by the
activity of endonucleases, proteases, degradation of cellular components and the
formation of apoptotic bodies52,53.
Necroptosis
Another form of cell death observed in renal IRI is necroptosis, commonly referred to
as regulated necrosis. Necroptosis exhibits characteristics of both necrosis and apoptosis.
Similar to the extrinsic pathway of apoptosis, necroptosis is a programmed form of cell
death initiated by the binding of a ligand, such as TNF- α, to its receptor on the surface of
cells54. This binding recruits receptor-interacting serine/threonine kinase 1 (RIPK1) and
receptor-interacting serine/threonine kinase 3 (RIPK3) proteins to form the
necrosome55,56. However, unlike apoptosis, this process is caspase independent57.
Downstream effects of necroptosis cause permeabilization of lysosomal membranes,
resulting in the release of lysosomal enzymes which lead to cellular and mitochondrial
damage, decreased ATP levels, and release of ROS58. The overall effects of necroptosis
result in cell death that morphologically resembles necrosis, which includes cell swelling,
eventual plasma membrane rupture, and release of intracellular contents which contribute
to inflammation59.
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Ferroptosis
Finally, ferroptosis has recently been implicated as a major form of cell death in
acute kidney injury and IRI60. Initiation of ferroptosis is dependent on the hyperactivity
of oxidation mechanisms in conjunction with impaired anti-oxidation mechanisms61.
While the exact mechanism of ferroptosis remains unclear, cellular events during IRI that
lead to lipid peroxidation, increased ROS and iron accumulation trigger ferroptosis within
the kidney62. Phenotypically, it is a necrotic type of cell death, similar to necrosis and
necroptosis, that leads to the release of DAMPs which contribute to inflammation63.
Markers of Cell Damage
Along with the induction of cell death pathways, injury from IRI leads to the
expression and release of proteins that can be used as biomarkers of acute kidney injury.
A key example explored in this thesis is the protein neutrophil gelatinase-associated
lipocalin (NGAL). NGAL is expressed at very low levels in a variety of tissue types
under normal conditions64. However, results from microarray analysis have indicated
NGAL to be one of the most robustly induced proteins in the kidney following ischemic
injury65. Additionally, in vitro studies have shown NGAL to be released into the culture
medium upon exposure to hypoxic conditions, and clinical studies have observed that
patients exhibit increased levels of NGAL in urine due to poor tubular reabsorption after
acute kidney injury64,66. As such, NGAL has drawn attention as a potential biomarker for
detecting acute injury from IRI. Other proteins that have been associated with damage
from renal IRI and explored as potential biomarkers are kidney injury molecule 1,
Cystatin C and interleukin-1867.

10

1.3.2

Activation of the Innate Immune Response
Another major consequence of ischemia reperfusion injury during kidney

transplantation is the activation of the innate immune response. As a result of cell damage
and death from IRI, normal cellular components are released from cells and components
of the extracellular matrix are degraded by proteolysis18. These components can act as
endogenous ligands, known as DAMPs, to activate the innate immune response within
the kidney68. Examples of these components that have been implicated in IRI during
kidney transplantation are: the non-histone chromatin binding protein high-mobility
group box 1 (HMGB-1), heat shock proteins, and extracellular matrix components
bigylcan and heparan sulfide, among others44,69–72. The tubular epithelial cells of the
kidney play an important role in the initiation of innate immune activation as they express
pattern recognition receptors that can recognize DAMPs73. Four classes of pattern
recognition receptors have been identified: Toll-like receptors (TLRs), C-type lectin
receptors, retinoic acid-inducible gene-1-like receptors and nucleotide binding and
oligomerization domain (NOD)-like receptors (NLRs)74. For this thesis, only pattern
recognition receptors that have been implicated in IRI during kidney transplantation will
be described.
The most well-studied pattern recognition receptors involved in IRI during kidney
transplantation are Toll-like receptors75. TLRs are a family of highly conserved
transmembrane proteins that consist of an extracellular leucine rich repeat domain and an
intracellular Toll/IL-1R (TIR) domain, which shares homology with the IL-1 receptor76.
There have been 11 TLRs identified in humans, which play various roles in responding to
stimuli77. Typically, TLRs respond to a variety of pathogen associated molecular patterns,
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for example, TLR4 specifically recognizes bacterial lipopolysaccharide (LPS)76. In renal
IRI, TLR 2, 3, 4 and 9 have been shown to be upregulated in kidney tissue and play a role
in perpetuating damage from IRI78–81. Ligand binding to TLRs triggers an intracellular
signaling cascade that culminates in the production of proinflammatory cytokines and
chemokines. All TLRs signal through the myeloid differentiation primary response 88
(MyD88) adaptor protein dependent pathway, except TLR3, which employs a TIRdomain containing adaptor-inducing interferon-β (TRIF) adaptor protein (MyD88independent pathway)74. Stimulation of the TLR/MyD88 pathway leads to the activation
of transcription factor, nuclear factor kappa light chain enhancer of activated B cells (NFkB), which translocates to the nucleus and promotes the production of pro-inflammatory
cytokines such as TNFα, IL-6 and various chemokines68. The TLR/MyD88 pathway also
leads to production of the precursor form of IL-1β and IL-18 (pro-IL-1β and pro-IL-18).
Similarly, stimulation of the TLR/TRIF pathway can activate NF-kB, however, TRIF is
also able to induce transcription factor, interferon regulatory factor 3 (IRF3), leading to
the production of type 1 interferons77.
Another pattern recognition receptor family that has recently been implicated in IRI
are NOD-like receptors82. NLRs are a family of 20 intracellular cytoplasmic proteins that
regulate the inflammatory and apoptotic responses83. There are two major classes of
NLRs important in renal IRI, the first is non-inflammasome-activating proteins
(NOD1/2), whose activation leads to the production of proinflammatory cytokines
through NF-kB activity83,84. The second class includes inflammasome-activating proteins,
most important of which is NLR pyrin domain containing 3 (NLRP3), that is highly
upregulated in renal tissue after IRI85. These proteins contribute to the activation of
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caspases and to the formation of the inflammasome complex. The inflammasome then
induces cleavage of pro-IL-1β and pro-IL-18 into their active forms18.
Ultimately, the activation of different pattern recognition receptors present in the
parenchymal cells of the kidney and on infiltrating leukocytes during IRI contribute to
the regulation of cell death and the inflammatory response by initiating the production of
proinflammatory cytokines and chemokines.

1.3.3

Inflammation
The culmination of cell death and activation of the innate immune response is the

perpetuation of inflammation within the transplanted organ. Two important aspects of the
inflammatory response in renal IRI are vascular changes and the recruitment of
leukocytes to the damaged tissue. Inflammatory mediators such as chemokines and
cytokines, including TNF-α and interleukins, play an important role in regulating the
inflammatory response to IRI86,87.
At the vascular level, swelling of endothelial cells and degradation of the
cytoskeleton from IRI disrupts endothelial cell-to-cell junctions which leads to increased
vascular permeability88. Additionally, damaged endothelial cells produce vasoactive
substances, such as platelet-derived growth factor and endothelin-1, which cause
vasoconstriction, further reducing blood flow to the post-ischemic kidney89. Activated
endothelial cells also exhibit increased expression of adhesion molecules and release of
pro-inflammatory cytokines which participate in leukocyte recruitment into the
allograft90. Specifically, the chemotaxis, adhesion, and transmigration of leukocytes, such
as neutrophils, is initiated by increased expression of P-selectins and endothelial cell
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adhesion molecule 1 on endothelial cells91. Leukocyte infiltration and activation within
the transplanted kidney contributes to graft damage and rejection90.
Overall, the effects of IRI lead to impaired function and increased
immunogenicity in the newly transplanted kidney, which jeopardizes the long-term
success of kidney transplant. Therefore, strategies to mitigate the complex consequences
of IRI at the time of transplant are critical to improving outcomes.

1.4 Organ Preservation
The severity of tissue damage from IRI depends on the length of cold and warm
ischemia and storage conditions. Consequently, ensuring optimal organ preservation at
the time of transplantation is critical for mitigating the impact of IRI, especially in DCD
donors. Therefore, strategies to improve organ storage conditions are at the forefront of
kidney transplantation research. This section will discuss the methods of organ
preservation currently employed in clinical practice, followed by the future directions in
the field.

1.4.1

Current Preservation Strategies

Since the beginning of transplantation, the state of organ preservation has been
regarded as a limitation to successful organ transplant92. Traditionally, cold storage on ice
has been used to reduce metabolic activity and improve graft viability93. Currently, there
are two main methods employed for organ storage. Both methods use an acellular
preservation solution to maintain intracellular ion concentrations and prevent cellular
edema during cold storage94. The University of Wisconsin (UW) solution is an example
of an intracellular fluid-type solution with low Na+ and high K+ levels, that is used as the
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standard of care preservation solution for abdominal organ95. The most common
preservation method is static cold storage (SCS), which involves the flushing and storage
of organs in a preservation solution on ice until the time of transplantation. This method
is simple to apply in the clinical setting and has proven to be effective for short term
organ storage96.
Another storage method that has gained popularity with the increased use of extended
criteria and DCD donor organs is hypothermic machine perfusion (HMP)97. This method
involves perfusing the organ with a preservation solution at 4 ºC until the time of
transplantation. HMP continuously provides metabolic substrates during storage to
support the production of ATP and improve tissue energy levels93. The use of HMP
decreases rates of delayed graft function and improve patient outcomes post-transplant
compared to SCS98, however, the organs still suffer substantial injury from cold
temperatures99. Therefore, strategies that can limit damage from cold and IRI, as well as
offer the opportunity for reconditioning of marginal organs, are the focus of current
research and will be explored in the next section.

1.4.2

Therapeutic Strategies in Organ Preservation

Kidney preservation strategies that maintain the organ in a more physiological
environment have gained popularity in recent research. The two main parameters being
investigated for their role in organ preservation are oxygenation and increased
temperature. Lack of oxygen to the kidney during the transplantation process is directly
related to the severity of injury observed post-transplant. As such, methods to provide
oxygen to the organ during storage are of interest. A study by Jochmans et al. compared a
novel method of hypothermic oxygenated machine perfusion versus traditional HMP for
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preservation of DCD kidneys during a phase III clinical trial. While there were no
significant differences observed in primary graft function, incidence of delayed graft
function or patient survival, episodes of acute rejection where higher in the HMP
group100.
More recently, methods that combine oxygenation with physiological temperatures
have been developed. The method that has been most studied is normothermic machine
perfusion (NMP), which refers to the ex vivo perfusion of organs at 37 ºC. Animal and
pre-clinical studies have shown NMP to be effective for improving immediate kidney
function, and reducing damage upon histopathological analysis101,102. Another method
that aims to reduce damage from cold IRI, while limiting metabolic demand exacerbated
by higher temperatures, is subnormothermic machine perfusion (SNMP). SNMP refers to
ex vivo organ perfusion between 20-34ºC. Research from our laboratory and others have
shown SNMP to be superior to SCS, HMP, and NMP in terms of preserving kidney
function and preventing damage from IRI in pre-clinical models of DCD kidney
transplantation103,104. While both NMP and SNMP require further investigation and
validation before they can be employed in the clinical setting, increased temperatures
allow for functional assessment of the organ prior to transplantation. Additionally, these
methods provide the opportunity for the application of drugs and additives to prevent
damage with higher efficiency than during cold storage.
As previously discussed, injury from IRI affects multiple cellular pathways, from
mitochondrial dysfunction, cell death pathways and activation of the innate immune
response, which damage the transplanted organ. Therefore, there are many potential
therapeutic targets available for mitigating damage from IRI. Our groups and others have
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seen success limiting IRI with the addition of pharmacological agents during preservation
in animal models and phase II trials105–108. Additionally, gene therapies, such as small
interfering RNAs for altering gene expression during IRI have shown some preliminary
success109,110. However, more evidence to validate the safety and efficacy of these
strategies is required before they can be implemented in clinic. Ideally, these
interventions will allow for superior organ preservation, preventing IRI, and even create
the possibility for organ reconditioning, thereby further expanding the pool of usable
organs.

1.4.3

Drug Repositioning in Kidney Transplant

While several therapies show promise for reducing tissue damage from IRI, new drug
development can take years from conception to use in patients. Therefore, an emerging
strategy in the pharmaceutical industry is drug repositioning or repurposing. Drug
repositioning refers to the use of a drug to treat a condition other than the one for which it
was initially approved111. This strategy allows for more efficient transition of drugs to
clinic, as dosage and safety data are already available. Therefore, clinically approved
drugs which may have secondary functions that are anti-inflammatory, anti-apoptotic or
can limit injury from IRI are of interest in organ preservation.
A key example of a repositioned drug is Metformin, which has recently drawn
attention for its renoprotective abilities112. Traditionally used as an anti-hyperglycemic
drug for the treatment of type II diabetes, the exact mechanism of action of Metformin is
still under investigation. Studies suggest it may reduce endothelial dysfunction and
activate cellular energy pathways 113–115, which may contribute to limiting damage from
IRI. Indeed, several studies have uncovered the protective effects of Metformin in
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cerebral and myocardial incidences of IRI116,117. Another drug with interesting secondary
function for IRI is Glyburide. While primarily used to treat type II diabetes, Glyburide
has been identified as a powerful inhibitor of the NLRP3 inflammasome118, which may
help control damaging downstream inflammation and immune activation in the context of
kidney IRI. Previous work in our laboratory has examined both Metformin and Glyburide
in the context of kidney IRI. Human kidney tubular epithelial cells (HK-2) were treated
with 100μM of Metformin or 200μM of Glyburide prior to undergoing hypoxia and
reoxygenation. Preliminary results showed an increase in ATP production in HK-2 cells
treated with Glyburide and Metformin compared to control, which may further indicate
their role in limiting damage from IRI. These drugs are promising examples of drug
repositioning in the context of IRI during kidney transplantation. However, to identify an
ideal candidate for improving kidney function and preventing damage from
transplantation, a large-scale screen of clinically approved drug candidates in the context
of kidney IRI is required.

1.5 Models of Ischemia-Reperfusion Injury
To screen existing drugs, a reliable model that encompasses relevant forms of
inflammation and injury observed in IRI during kidney transplantation is necessary.
While many in vivo models exist to evaluate renal IRI, the focus of this section will be in
vitro models, which provide the most relevant platform to perform drug screening and
mechanistic analysis.

18

First, cell type is an important consideration when selecting an in vitro model of renal
IRI. The kidney is composed of many cell types, such as tubular epithelial cells and
endothelial cells, which respond differently to IRI119. Most models focus on renal
proximal tubular epithelial cells due to their increased susceptibility to ischemic insult
and crucial functional role within the kidney120. Primary tubule cells can be isolated from
human or animal kidneys and provide an excellent tool to study kidney injury with the
most similar behaviour to cells in vivo121. However, purity of cell type, inconsistency in
results and longevity of cells are limitations that compromise the suitability of primary
cells for an in vitro model122. An alternative to primary cells are immortalized cell lines
which produce more consistent results, are well-characterized, and can be used for a
longer duration123. Several renal proximal tubule cell lines exist, including human (HK-2
and RPTEC/TERT), rat (NRK-2) and pig (LLC-PK1), which have been used for in vitro
models of kidney IRI. Promising results for identifying cell death, markers of hypoxia,
inflammation and injury have been achieved in IRI studies with these cell lines124–127.
However, these cells can exhibit some gene expression patterns not observed in vivo and
must also be monitored throughout their use for dedifferentiation and transformation128.
Therefore, it is important to select a cell type that best suits the purpose of the studies to
be performed.
Another key aspect of studying IRI in vitro is the method of hypoxia and
reoxygenation. A broad range of methods have been used to create hypoxic environments
and nutrient deprivation for the study of renal IRI. Some studies utilize hypoxia chambers
to keep cells between 0% -5% O2105,129–131, others submerge cells under a monolayer of
mineral oil to induce hypoxic conditions 79,132, both typically in combination with glucose
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or nutrient deprivation. Other methods involve chemically mimicking the cellular
conditions observed during IRI such as decreased pH, nutrient depletion, and ROS
generation133. This is accomplished by culturing cells in physiological salt solutions
without metabolic substrates, and in the presence of additive such as lactate acid or
hydrogen peroxide134,135.
Additionally, the length of time that cells are exposed to hypoxia and reoxygenation
varies between models. The length of hypoxia ranges from 15 min to 24hr and
reoxygenation lasts between 5 min to 24hr depending on the experimental model and
assessments124,125,129–131. Similarly, depending on the aim of the study, temperatures
between 4 ºC - 37 ºC have been used for storage of cells during hypoxia, whereas 37ºC is
used consistently for reoxygenation79,105,136–138. As the temperature and length of hypoxia
and reoxygenation periods affect the observed outcomes, it is important to select
conditions that accurately mimic the injury being studied.

1.6 Rationale
The goal of our research is to improve the field of organ preservation by applying
therapeutics that can limit the damage from IRI during kidney transplantation. Drug
repositioning through large-scale screening of clinically approved drug candidates is a
promising approach for identifying an effective therapeutic that can be easily translated
into clinical use. Due to the lack of consistency and different uses of in vitro models to
study renal IRI, the development of an in vitro model that mimics the injury observed in
DCD kidney transplantation is required for effective and relevant drug testing. The
development and characterization of such a model will facilitate the screening and study
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of the efficacy and mechanism of action of drug candidates against IRI in kidney
transplant, prior to their application in our pre-clinical models.

1.7 Hypothesis Statement
We hypothesize that our hypoxia and reoxygenation model will exhibit increased
cell death, damage, and markers of inflammation characteristic of renal IRI. Additionally,
we expect our model can be an effective tool to screen drug candidates for their
therapeutic potential against IRI.

1.8 Specific Aims
In order to test our hypothesis, we aim to: 1) establish an in vitro model of IRI
using human tubular epithelial cells to mimics clinical DCD kidney transplantation, 2)
investigate inflammation and innate immune activity in the established IRI model and 3)
to test the efficacy of the in vitro model as a screening tool with select drug candidates.
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Chapter 2

2

Materials and Methods

2.1 HK-2 Cell Culture
Maintenance of cell line
Human tubular epithelial cells (HK-2; ATCC, VA, USA) were maintained in
Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12; ThermoFisher
Scientific) supplemented with 10% fetal bovine serum (FBS; Gibco), 1% penicillinstreptomycin (Gibco), 1.0 mg/mL recombinant human insulin, 0.55mg/mL human
transferrin and 0.5 ug/mL sodium selenite (1 X ITS; Sigma-Aldrich), 5ng/mL epidermal
growth factor (EGF; ThermoFisher Scientific), referred to as complete media. Cells were
kept in a humidified incubator (37 ºC; 5% CO2; 21% O2).

Cell culture: To passage, adherent cells were washed with warm 1X phosphate
buffered saline (PBS; Wisent) prior to treatment with 1mL 0.25% trypsin-EDTA
(Wisent) at 37 ºC for 1 min. Trypsin was diluted with 9 mL complete media (DMEM/F12). Cells were collected and pelleted by centrifugation (125xg ; 5 min). Cells were
resuspended in the appropriate volume of complete media (1:4) and re-plated for
experiments or continued growth. All cells were used below the 20th passage.

2.2 Establishment of Hypoxia and Reoxygenation
Conditions
To achieve ideal storage conditions, several storage solutions with different
compositions were tested (Table 2-1). HK-2 cells grown to 90% confluence were
subjected to 1hr of hypoxia at 37 ºC using a hypoxia chamber (HypOxygen), 24hr of
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hypoxia at 4 ºC using a GenBag and 24hr of reoxygenation at 37 ºC in a humidified
incubator. Complete media, serum-free media or D-Hanks Buffer were used for warm
hypoxia. Serum-free media and/or UW solution (Bridge to Life Ltd.) was used during
cold storage. Finally, either complete media or complete media supplemented with UW
solution from hypoxia was used for reoxygenation. After undergoing the various IRI-like
conditions, cell death was measured using live cell imaging and flow cytometry. HK-2
cells grown to 90% confluence at 37 ºC in complete media were used as a control for all
experiments.
In addition, for the control cell death study for the UW supplementation group
during reoxygenation, 90% HK-2 cells were incubated with 25% UW solution in 75%
complete media (v/v) for 24hr at 37 ºC. Cells were analyzed for viability using flow
cytometry.
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Table 2- 1. Storage solutions tested during phases of hypoxia and reoxygenation.
Warm Hypoxia

Cold Storage

Reoxygenation

Abbreviation

Serum-free media

Serum-free media

Complete media

SF

Serum-free media

UW Solution

Complete media

SFUW

Complete media

UW solution

Complete media

CompUW

Serum-free media

UW solution

Complete media + 25% UW

SFUW+

D-Hanks Buffer

UW solution

Complete media

DHUW

D-Hanks Buffer

UW solution

Complete media + 25% UW

DHUW+
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2.3 In vitro Model of Ischemia Reperfusion Injury
The established model conditions concluded from above were used for all
subsequent experiments (Figure 2-1). Fresh HK-2 cells were seeded at in a 10cm, 6-well
plate, or 24-well plate depending on assay type and grown to 90% confluence. Cells were
subjected to 1hr warm hypoxia at 37 ºC in a hypoxia chamber (HypOxystation®) in DHanks’s Buffer, prepared in house (Table 2-2). Subsequently, D-Hanks Buffer was
replaced with UW preservation solution (Table 2-3) and cells were subjected to cold
storage at 4 ºC for 24hr using a GenBag (BD Bioscience). After cold storage, 50% of UW
solution was removed and 50% was kept to supplement media for a final volume of 25%
UW solution. Fresh media was added to cells, and they were grown for 24hr under
normal oxygen conditions at 37 ºC. Post-reoxygenation, cells and supernatants were
collected for analysis.

Figure 2-1. Simplified design for an in vitro model of ischemia reperfusion injury in
kidney transplantation.
A summary of the experimental conditions used in subsequent experiments to validate the
model and used for preliminary drug testing.
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Table 2-2. 1x D-Hanks Buffer prepared for physiological storage of HK-2 cells during
warm hypoxia.
Component

Concentration
(mM)

NaCl

140

KCl

5

CaCl2

1

MgSO4 – 7H2O

0.4

MgCl2 – 6H2O

0.5

Na2HPO4 – 2H2O

0.3

KH2PO4

0.4

D-Glucose (Dextrose)

6

NaHCO3

4

Table 3-3. Composition of Bridge to Life UW preservation solution139 used for storage of
cells during cold hypoxia.
Component

Concentration

Hydroxyethyl starch

50 g/L

Lactobionate

100 mM

Raffinose

30 mM

Na+

30mM

K+

125mM

Mg2+

5mM

SO42-

5mM

PO43-

25mM

Allopurinol

1mM

Glutathione

3mM

Adenosine

5mM

Insulin

40 U/L
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2.4 Confirmation of Hypoxia
2.4.1

Measurement of HIF-1α via ELISA
To measure HIF-1α, HK-2 cells were plated in a 10cm plate and grown to 90%

confluence. Control samples were collected for nuclear extraction. Hypoxia samples were
subjected to 1hr warm hypoxia and 24hr cold hypoxia as previously described. Prior to
reoxygenation, nuclear and cytoplasmic extracts were prepared using a nuclear extraction
kit (Active Motif) as per the manufacturer’s protocol. Briefly, cells were washed with
5mL ice cold PBS with phosphatase inhibitors. Cells were collected in PBS and
centrifuged at 200xg for 5min. Cells were resuspended in 1x hypotonic buffer and
incubated on ice for 15min. Cytoplasmic fractions were isolated by centrifuging samples
at 14,000xg for 1min at 4 ºC and supernatants were collected. Nuclear extracts were
prepared by resuspending cell pellets in 50uL of complete lysis buffer and incubating
suspension for 30min at 4 ºC. Finally, samples were centrifuged for 10min at 14,000xg
followed by collection of supernatants. Nuclear extracts were analyzed for the presence
of HIF-1α protein using ELISA.

2.4.2

Non-Hypoxic Cells as a Negative Control for Hypoxia
HK-2 cells were grown to 90% confluence in a 6-well plate. At this point cells

were subjected to the IRI storage conditions without hypoxia. In summary, cells were
stored in D-Hanks Buffer for 1hr at 37 ºC in a humidified incubator (5% CO2, 21%O2),
followed by storage at 4 ºC for 24hr in UW solution. Then, cells were incubated in
complete media + 25% UW solution from cold stage, for 24hr at 37ºC. Viability of cells
was assessed using flow cytometry.
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2.5 Incubation of HK-2 Cells with TLR Ligands
2.5.1

Stimulation with Lipopolysaccharide
Fresh HK-2 cells were plated on a 24-well plate and grown to 90% confluency.

Cells were treated with 1μg/mL of lipopolysaccharide (LPS) in fresh DMEM/F-12 media
and incubated at 37 ºC for 12hr. Cell culture supernatants were used for analysis with
ELISA.

2.5.2

Stimulation with DAMPs from Conditioned Media
Fresh HK-2 cells were plated on a 24-well plate and grown to 90% confluency.

Cells were treated with 500μL conditioned media from IRI-treated cells and incubated at
37 ºC for 24hr. After the incubation period, cell culture supernatants were collected for
analysis with ELISA.

2.6 Drug Testing
Fresh HK-2 cells were plated on either a 24-well plate for supernatant or 6-well
plate for cell death assays and grown to 90% confluence. Metformin treatment was
prepared as follows: Metformin stock solution (1.5mM) was diluted to 100μM using
complete media and 50mM stock of Glyburide was diluted to 200μM in complete media.
Cells were pre-treated with either 1) 100μM of Metformin or 2) 200μM of Glyburide for
6hr prior to undergoing IRI treatment as previously described. After reoxygenation, cell
supernatants were obtained for multiplex ELISA analysis (Eve Technologies
Corporation) and cell death was measured using flow cytometry. Drug concentrations
were selected based on a previous study in our laboratory.
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2.7 Cell Death Assays
2.7.1

Real-Time Cell Death via InCucyte Monitoring
After subjecting cells to warm hypoxia and cold storage in the previously

described conditions, cell death was dynamically monitored during 24hr of reoxygenation
using an InCucyte® (InCucyte ZOOM, Sartorius) to assess cell death in real time. To
detect cell death, 1μg/mL of Propidium Iodide (PI, Thermo Fisher Scientific) was added
to each well immediately prior to reoxygenation. The InCucyte captured 9 images of
phase and red fluorescence at 4x magnification per well during each hour of
reoxygenation. Red objects indicate PI positive staining of DNA, representing cell death.
Red objects were counted by the InCucyte software per well between the 9 images and
were plotted against time at each hour to produce a cell death curve.

2.7.2

Cell Death and Apoptosis Quantification with Flow Cytometry
At the experimental endpoints, select samples were analyzed for cell viability and

apoptosis. Cell culture supernatants were collected into labeled FACS tubes. Each well
was washed with 500μL of 1X PBS to remove any traces of FBS. Subsequently, 500μL
of 0.25% trypsin-EDTA was added to each well and plates were incubated at 37ºC for
2min to facilitate detachment of the cells. Following incubation, 500μL of complete
media was added to each well to inactivate the trypsin. The media containing the
detached cells was collected and added into the labeled FACS tubes. The FACS tubes
were centrifuged for 5min at 125xg to pellet cells. The cells were resuspended in 1X PBS
and centrifuged again at 125xg for 5min. Next, cells were resuspended in 200μL of 1x
Annexin-V Binding Buffer (BioLegend). After resuspension, 1μL of FITC-conjugated
Annexin V (FITC-Annexin V; BD BioScience) and 3μL of 7-Aminoactinomycin (7-
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AAD; eBioScience) were added to each sample to stain for apoptosis and cell death
respectively. Samples were incubated with stains in the dark for 15min prior to analysis.
Samples were analyzed using the CytoFLEX S (Beckman Coulter) using the following
laser gains for the respective channels: 200 FSC, 100 SSC, 10 FITC, 5 PC5.5.
Compensation was conducted using 1) unstained live cells, 2) heat-killed cells (90 ºC for
10min) stained with Annexin V only, 3) heat-killed cells stained with 7-AAD only and 4)
heat-killed cells stained with both Annexin V and 7-AAD. FlowJo V10 (FlowJo LLC)
was used to gate data for statistical analysis.

2.8 Enzyme-Linked Immunosorbent Assay (ELISA)
The levels of damage associated molecular pattern, HMGB-1, kidney damage
marker, NGAL, and inflammatory marker, IL-6, secreted in HK-2 cell culture media
were measured by ELISA (MyBioSource) from control cells, post-reoxygenation (IRI)
and LPS-treated cells. Cell culture supernatants were centrifuged at 3000xg for 10 mins
to remove debris. The amount of HIF-1α protein present in nuclear extracts from control
or HK-2 cells subjected to warm and cold hypoxia conditions (Hypoxia) was also
detected using an ELISA (Abcam). HIF-1α samples were prepared as previously
described. A 1:10 dilution was performed on all samples prior to assay. ELISA kits were
used according to the manufacturer’s protocol. Briefly, 100μL of standards and samples
were incubated in the pre-coated ELISA plates for 1hr. After washing, 100μL of
biotinylated detection antibody was added to the plates and incubated for 1hr. Plates were
washed and 100μL of avidin-HRP working solution was added for 1hr. Following a final
wash, substrate reagent was added to the plate and the colour was developed. Plates were
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read at 450nm using an iMark microplate reader (BioRad). Concentrations of the target
proteins in the samples were determined from the standard curve.

2.9 Multiplex ELISA
Cell culture supernatants from control, hypoxia, LPS, drug-treated and
conditioned media treated cells were collected at the previously described endpoints.
Samples were centrifuged at 3000xg for 10 mins at 4ºC. Immediately after centrifugation,
samples were aliquoted and stored at -80 ºC. Samples were sent to Eve Technologies
(Alberta, Canada) for cytokine detection using Luminex xMAP technology.

2.10 Statistical Analysis
All statistical analyses were conducting using GraphPad Prism Version 9.
Student’s t-test or one-way analysis of variance (ANOVA) and Tukey’s post-hoc test was
performed to determine statistical differences. Data is represented as the mean ± SEM of
a minimum of five independent experiments (n=5), unless otherwise stated. Statistical
significance was accepted at p<0.05.
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Chapter 3

3

Results

3.1 Optimization of in vitro DCD IRI model conditions
To determine the optimal treatment conditions necessary to cause significant cell
death, implying relevant conditions to IRI during DCD kidney transplant, HK-2 cells
were subjected to hypoxia and reoxygenation in various storage solutions. Results from
live-cell imaging during reoxygenation (Figure 3-1A) and flow cytometry (Figure 3-1BD) analysis identified D-Hanks Buffer during warm hypoxia and UW solution during
cold storage solution, followed by reoxygenation with UW supplementation (DHUW+)
to be the most suitable conditions for storage based on cell death parameters. This
condition will be referred to as simulated IRI (sIRI) in subsequent sections.

Additionally, since UW solution contains a high potassium concentration, we
wanted to ensure that the cell death observed in the DHUW+ group was not due to the
presence of UW solution at warm temperatures. To confirm this, we incubated fresh HK2 cells with 25% UW solution and 75% complete media (v/v) for 24hr and measured cell
death. Analysis using flow cytometry indicated that UW under warm conditions is not
sufficient to elicit the cell death observed in the DHUW+ condition (Figure 3-2).
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(A)

(B)

33

(C)

(D)

Figure 3-1. Cell death is dependent on storage solution.
HK-2 cells were subjected to 1hr of warm hypoxia at 37 ºC, 24hr of cold storage at 4 ºC
followed by 24hr of reoxygenation at 37 ºC in serum-free media (SF), SF, complete
media or D-hanks Buffer followed by UW solution (SFUW, Comp UW, DHUW), or
SFUW and DHUW with 25% UW supplementation during reoxygenation (SFUW+,
DHUW+). Cell death was monitored with (A) live-cell imaging during the reoxygenation
phase using propidium iodide to label and count dead cells (red objects). Post
reoxygenation, cell death was analyzed with (B) flow cytometry using Annexin V and 7AAD staining. Flow cytometry results were quantified for (C) cell viability (n=5) and (D)
apoptosis (n=5). Data is represented as the mean ± SEM.
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(A)

(B)

(C)

Figure 3-2. Cell death is due to sIRI conditions and not presence of UW solution.
HK-2 cells were treated with 25% UW solution in complete media for 24hr at 37 ºC
(control +UW) or subjected to 1hr of warm hypoxia in D-Hanks Buffer at 37 ºC, 24hr of
cold storage in UW solution at 4 ºC and 24hr of reoxygenation in complete media
supplemented with 25% UW solution from storage at 37 ºC (DHUW+). Post
reoxygenation, cell death was analyzed using (A) flow cytometry by staining for Annexin
V and 7-AAD. Quantification of (B) cell viability and (C) apoptosis from flow
cytometry results of 3 separate experiments (n=3) showed no significant difference in
death between control and control +UW conditions. Data is represented as the mean ±
SEM. Means were analyzed using one-way ANOVA and Tukey’s post-hoc test. ****
p<0.000001.
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3.2 sIRI conditions induce cell death in HK-2 cells
An important aspect of IRI is the activation of cell death pathways. For our
model, we wanted to confirm if our applied conditions were able to induce cell death in
HK-2 cells. We measured this during the reoxygenation stage by staining cells with DNA
stain, propidium iodide, and monitoring with live cell imaging. Increased propidium
iodide staining was detected in cells that had experienced sIRI compared to control
(Figure 3-3).
Additionally, cell death was quantified after reoxygenation by detecting Annexin
V and 7-AAD positive cells with flow cytometry (Figure 3-4A). Annexin V detects
plasma membrane component, phosphatidylserine, that is exposed to the external
environment during apoptosis. 7-AAD binds double stranded DNA from cells without an
intact plasma membrane. Upon analysis, cell viability was significantly reduced in cells
that had undergone sIRI compared to control (Figure 3-4B). Additionally, apoptosis, as
quantified by Annexin V positive cells, was significantly increased in sIRI (Figure 3-4C).
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(A)

(B)

Figure 3-3. Cell death during sIRI is dependent on length of reoxygenation
HK-2 cells were subjected to control or sIRI. Prior to reoxygenation, cells were stained
with propidium iodide (PI) and monitored with live cell imaging for 24hr during
reoxygenation. (A) Images show increased red staining in IRI cells after 24hr. (B) A
linear increase in cell death, as indicated by PI-positive cells, was observed in the IRI
cells during reoxygenation compared to only a slight increase observed in control cells.
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(A)

(B)

C)

Figure 3-4. IRI model activates cell death pathways.
HK-2 cells were subjected control or sIRI conditions. Post reoxygenation, cell death was
analyzed using (A) flow cytometry by staining for Annexin V and 7-AAD.
Quantification of (B) cell viability and (C) apoptosis from flow cytometry results of 5
separate experiments (n=5) showed a significant increase in cell death in sIRI conditions
compared to control. Data is represented as the mean ± SEM. Means were analyzed using
Student’s t-test. **** p<0.000001.
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3.3 Hypoxic conditions are achieved in the IRI model
To confirm hypoxic conditions were achieved by our sIRI conditions, the
presence of a hypoxic environment was investigated in two ways. First, the amount of a
well-known marker of hypoxia, HIF-1α, a protein that is degraded under normal oxygen
conditions but accumulates and translocates to the nucleus upon hypoxic conditions, was
measured in cells that had undergone sIRI and control cells. Cells that experienced sIRI
expressed more HIF-1α than controls (Figure 3-5), indicating they were exposed to a
hypoxic environment.
Additionally, a negative control experiment was conducted to assess what
percentage of cell death could be attributed to sIRI storage conditions alone. HK-2 cells
were subjected to sIRI storage conditions, consisting of 1hr in D-Hanks buffer at 37 ºC
followed by 24hr in UW solution at 4 ºC, in a normal oxygen environment. Results
indicated no significant difference in cell death between control and no hypoxia (negative
control) conditions, whereas significantly more cell death was observed in cells subjected
to sIRI (Figure 3-6).
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Figure 3-5. Increased levels of HIF-1α were detected in sIRI conditions.
HK-2 cells were subjected to 1hr of warm hypoxia in D-Hanks buffer at 37 ºC followed
by 24hr of cold storage in UW solution at 4 ºC under hypoxic conditions. Prior to
reoxygenation, levels of the protein HIF-1α in cellular extracts was assessed using
ELISA. Results of 5 separate experiments (n=5) showed a significant increase in levels of
HIF-1α in hypoxia-treated cells compared to untreated cells (control). Data is represented
as the mean ± SEM. Means were analyzed using Student’s t-test. *p<0.05.
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(A)

(B)

(C)

Figure 3-6. Effect of sIRI on cell death.
HK-2 cells were subjected to sIRI conditions of 1hr storage in D-Hanks buffer at 37 ºC
and 24hr in UW solution at 4 ºC followed by 24hr reoxygenation in UW-supplemented
complete media at 37 ºC, with (sIRI) or without hypoxia (No Hypoxia). Post
reoxygenation, cell death was analyzed using (A) flow cytometry by staining for Annexin
V and 7-AAD. Quantification of (B) cell viability and (C) apoptosis from flow
cytometry results of 3 separate experiments (n=3) showed a significant increase in cell
death in sIRI conditions compared to both no hypoxia and control conditions. Data is
represented as the mean ± SEM. Means were analyzed using one-way ANOVA and
Tukey’s post-hoc test. *** p<0.001, **** p<0.000001.
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3.4 sIRI leads to increased release of damage markers
Another important feature of IRI during kidney transplantation is the release of
cellular material and proteins as a consequence of cell death and damage, which serve as
markers of injury or can act as danger molecules to stimulate the innate immune
response. To further investigate whether our model accurately mimics the conditions of
IRI during DCD kidney transplantation, we measured the release of two damage markers
after subjecting cells to sIRI conditions. First, we looked at damage-associated molecular
pattern, HMGB-1, which is a nuclear protein that is released from cells during necrosis or
necrosis-like cell death. This molecule can act as an endogenous ligand to stimulate
innate immune activity. Analysis of cell culture supernatants using ELISA indicated a
significantly higher level of HMGB-1 detected in sIRI-treated cells compared to controls
(Figure 3-7A). Additionally, we looked at the secretion of the kidney specific injury
marker, NGAL. Levels of NGAL in supernatants of sIRI-treated cells were significantly
elevated compared to controls (Figure 3-7B).
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(A)

(B)

Figure 3-7. sIRI conditions lead to the release of relevant cell damage markers.
HK-2 cells were subjected to sIRI conditions of 1hr warm hypoxia in D-Hanks buffer at
37 ºC and 24hr of hypoxia in UW solution at 4 ºC followed by 24hr reoxygenation in
UW-supplemented complete media at 37 ºC or no sIRI treatment (control). Levels of (A)
high mobility group box 1 (HMGB-1) and (B) neutrophil gelatinase-associated lipocalin
(NGAL) in cell culture supernatants were measured by ELISA, n=3. Data is represented
as the mean ± SEM. Means were analyzed using Student’s t-test. *p<0.05, ** p<0.01.
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3.5 sIRI leads to production of pro-inflammatory cytokines
The inflammatory response is an important part of stimulating and perpetuating
the injury from IRI during kidney transplantation. To investigate whether our model
conditions were able to produce pro-inflammatory cytokines known to be involved in
IRI, cell culture supernatants were analyzed for multiple cytokines using multiplex
ELISA. From the cytokines tested, we observed significantly elevated levels of several
pro-inflammatory cytokines in sIRI supernatants compared to control (Figure 3-8). This
indicates that our model is able to produce cytokines relevant to the inflammatory
response seen during renal IRI.
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Figure 3-8. Pro-inflammatory cytokines are produced during sIRI.
HK-2 cells were subjected to sIRI conditions of 1hr warm hypoxia in D-Hanks buffer at
37 ºC and 24hr of hypoxia in UW solution at 4 ºC followed by 24hr reoxygenation in
UW-supplemented complete media at 37 ºC or no IRI treatment (control). Cell culture
supernatants post-reoxygenation were analyzed for pro-inflammatory cytokines (A) IL-6,
(B) IL-8, (C) GM-CSF, (D) IFN and (E) TNF- α using multiplex ELISA, n=3. Data is
represented as the mean ± SEM. Means were analyzed using Student’s t-test. ***
p<0.001, **** p<0.000001.
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3.6 sIRI conditions stimulate the innate immune response
The activation of innate immune receptors on parenchymal and immune cells by
DAMPs leads to the production of pro-inflammatory cytokines during renal IRI. To
confirm if any signaling pathways related to innate immune activation are triggered in
HK-2 cells, we used a natural TLR4 ligand, lipopolysaccharide (LPS), to stimulate TLR
activity. We compared the levels of IL-6 secreted into cell culture supernatants, a
downstream product of TLR4 signaling, in both LPS stimulated and sIRI treated HK-2
cells. We observed that levels of IL-6 were elevated in both the sIRI and LPS conditions
compared to control cells (Figure 3-9), indicating that innate immune activity is present.
Interestingly, stimulating with LPS or sIRI conditions were able to produce similar levels
of IL-6.
To further assess whether DAMPs from HK-2 cells exposed to sIRI could activate
naïve cells, we incubated fresh HK-2 cells with cell culture supernatants from sIRItreated cells (conditioned media), which should contain DAMPs such as HMGB-1. Upon
analysis, conditioned media was not able to elicit cell death in HK-2 cells (Figure 3-10),
however, it was able to stimulate the production of pro-inflammatory cytokines to similar
levels as sIRI (Figure 3-11).
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Figure 3-9. Interleukin-6 production in HK-2 cells through TLR stimulation
HK-2 cells were either incubated with 1μg/mL of LPS for 12hr (LPS) or subjected to 1hr
warm hypoxia in D-Hanks buffer at 37 ºC and 24hr of hypoxia in UW solution at 4 ºC
followed by 24hr reoxygenation in UW-supplemented complete media at 37 ºC (sIRI).
Levels of IL-6 in cell culture supernatants (n=5) were measured using ELISA. Data is
represented as the mean ± SEM. Means were analyzed using one-way ANOVA and
Tukey’s post-hoc test. *** p<0.001, ns p>0.05.
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A)

(B)

C)

Figure 3-10. Conditioned media does not trigger cell death.
HK-2 cells were incubated with conditioned media from sIRI treatment for 24hr
(Conditioned Media). Post reoxygenation, cell death was analyzed using (A) flow
cytometry by staining for Annexin V and 7-AAD. Quantification of (B) cell viability and
(C) apoptosis from flow cytometry results of 5 separate experiments (n=5) showed no
significant difference in cell death between treatment with conditioned media and control
conditions. Data is represented as the mean ± SEM. Means were analyzed using
Student’s t-test. ns p>0.05.
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Figure 3-11.Conditioned media leads to the production of pro-inflammatory cytokines
HK-2 cells were subjected to 1hr hypoxia in D-Hanks buffer at 37 ºC and 24hr of
hypoxia in UW solution at 4 ºC followed by 24hr reoxygenation in UW-supplemented
complete media at 37 ºC (sIRI) or incubated with conditioned media from sIRI treatment
for 24hr (Conditioned Media). Cell culture supernatants (n=3) post-reoxygenation were
analyzed for pro-inflammatory cytokines (A) IL-6, (B) IL-8, (C) GM-CSF, (D) IFN and
(E) TNF- α using multiplex ELISA. Data is represented as the mean ± SEM. Means were
analyzed using one-way ANOVA and Tukey’s post-hoc test. *p<0.05, ** p<0.01, ***
p<0.001, ns p>0.05.
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3.7 IRI model can be used for drug testing
As our future goal is to use the developed IRI model for large scale drug
screening, we wanted to ensure it provided an effective and reliable platform for drug
testing. To investigate this, we selected two candidate drugs, namely Metformin and
Glyburide, which were previously explored for their role in reducing injury from IRI in
our laboratory. HK-2 cells were pre-treated with either 100μM Metformin or 200μM
Glyburide prior to sIRI treatment. The ability of the drug treatments to reduce cell death
were analyzed with flow cytometry (Figure 3-12A). Neither Metformin nor Glyburide
was able to significantly improve cell viability or apoptosis post reoxygenation (Figure 312B,C).
Furthermore, to test whether drug treatments were able to reduce inflammation,
which is relevant to reducing damage from IRI, cell culture supernatants were analyzed
for pro and anti-inflammatory cytokines with multiplex ELISA. Both Glyburide and
Metformin treatment were able to significantly reduce the levels of IL-6, IL-8 and GMCSF compared to sIRI treatment alone (Figure 3-13A-C). Additionally, Glyburide
treatment was also able to significantly reduce IFN and TNF- α levels (Figure 3-13D,
E). Interestingly, while not significant, Metformin treatment showed increased levels of
anti-inflammatory cytokines (Figure 3-13F-H).
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A)

B)

C)

Figure 3-12. Drug treatment does not reduce cell death in IRI model.
HK-2 cells were pre-treated with either 100μM Metformin (sIRI + Metformin) or 200μM
Glyburide (sIRI + Glyburide) for 6hr prior to being subjected to 1hr hypoxia in D-Hanks
buffer at 37 ºC and 24hr of hypoxia in UW solution at 4 ºC followed by 24hr
reoxygenation in UW-supplemented complete media at 37 ºC (sIRI). Post reoxygenation,
cell death was analyzed using (A) flow cytometry by staining for Annexin V and 7-AAD.
Quantification of (B) cell viability and (C) apoptosis from flow cytometry results (n=3)
indicated no change in cell death between either Metformin or Glyburide pre-treatment
compared to sIRI conditions alone. Data is represented as the mean ± SEM. Means were
analyzed using one-way ANOVA and Tukey’s post-hoc test. * p<0.05, ns p>0.05.
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Figure 3-13. Drug treatment alters cytokine levels in IRI model.
HK-2 cells were pre-treated with either 100μM Metformin (sIRI + Metformin) or 200μM
Glyburide (sIRI + Glyburide) for 6hr prior to being subjected to 1hr hypoxia in D-Hanks
buffer at 37 ºC and 24hr of hypoxia in UW solution at 4 ºC followed by 24hr
reoxygenation in UW-supplemented complete media at 37 ºC (sIRI). Following
reoxygenation, levels of pro-inflammatory cytokines (n=3)(A) IL-6, (B) IL-8 (C) GMCSF (D) IFN and anti-inflammatory cytokines (F) IL-4, (G) IL-10 and (H) IL-13 were
measured using multiplex ELISA. Data is represented as the mean ± SEM. Means were
analyzed using one-way ANOVA and Tukey’s post-hoc test. *p<0.05, ** p<0.01, ***
p<0.001, **** p<0.000001, ns p>0.05.
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Chapter 4

4

Discussion
IRI remains a major clinical problem in kidney transplantation as it has been linked to

increased rates of DGF, prolonged hospitalization, acute graft rejection and early graft
loss140. Improving organ preservation prior to transplantation can mitigate damage from
IRI93. Currently, the clinical standard for organ preservation is either static cold storage
or non-oxygenated hypothermic machine perfusion at 4 ºC using a preservation solution,
such as UW solution93. While these methods are effective for reducing metabolic demand
and promoting cell survival pretransplant, the grafts still experience injury from cold
ischemia141. To improve preservation, recent research in transplantation has focused on
creating more physiological conditions for organ storage. Several groups have shown
success with normothermic and subnormothermic oxygenated perfusion
methods103,142,143. However, current preservation solutions are ineffective at warmer
temperatures and they cannot carry oxygen to be delivered to the organ144,145. Therefore,
identifying an optimal perfusion solution for NMP or SNMP is of interest. Our group has
successfully utilized a hemoglobin-based oxygen carrier (HBOC) during SNMP to
improve kidney function, reduce acute tubular necrosis and levels of pro-inflammatory
cytokines in a porcine model of DCD kidney transplantation146. Despite this
improvement, damage from IRI still persists. As such, we aim to apply existing drugs or
small molecules that can further target damage from IRI to perfusates during organ
storage. Since screening and mechanistic study of drug candidates cannot be efficiently
executed in animal models, an in vitro model that accurately mimics the damage from
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renal IRI is required. In this study, we designed and characterized an in vitro model of
IRI that mimics the injury and conditions of DCD kidney transplantation, which can be
used to screen and study the therapeutic effects of drug candidates.

First, we established a model that mimicked the warm ischemia before organ
procurement, cold ischemic time during prolonged storage and reperfusion posttransplant in the recipient, as observed in DCD kidney transplantation (Figure 2-1). From
these conditions, we were able to induce cell death in human tubular epithelial cells
(Figure 3-4), which are the main target of damage during IRI21. This finding was
consistent with other models of renal IRI, which show between 50-65% cell death from
IRI conditions depending on cell type and methods used105,147. Additionally, in the
clinical setting, increased apoptosis of tubular epithelial cells is observed and is highly
correlated with the severity of ischemia reperfusion injury48. Cell death is a major
consequence of IRI during kidney transplantation that contributes to poor function posttransplantation and promotes further damaging factors such as innate immune activation
and inflammation. Therefore, the presence of cell death in our model was important for
mimicking the clinical conditions of renal IRI.

Next, we investigated the ability of our model to produce organ specific damage
markers. Several biomarkers have been identified in the clinical setting for detecting
acute kidney injury from IRI148. In this study, we specifically looked at the secretion of
neutrophil gelatinase-associated lipocalin (NGAL), which has previously been shown to
be upregulated and secreted by HK-2 cells in other in vitro models of renal IRI149. We
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detected increased levels of NGAL in cell culture supernatants post-reoxygenation in our
IRI conditions compared to control cells (Figure 3-7B). This finding correlates with
clinical data, where urine levels of NGAL are significantly elevated post-transplantation
and predictive of poor graft function150. Therefore, detection of increased NGAL levels in
our model confirms a relevant form of cellular injury has occurred and provides a kidney
specific injury marker that can be used to monitor cell damage.

Further, we considered the ability of our model to produce pro-inflammatory
cytokines, which are key in perpetuating damage and increasing immunogenicity in the
kidney post-transplant. In this study, we looked at the levels of several pro-inflammatory
cytokines in cell culture supernatants post-reoxygenation. We observed significantly
increased secretion of IL-6, IL-8, GM-CSF, IFN and TNF- α in HK-2 cells that
underwent our IRI conditions compared to controls (Figure 3-8). This finding is
important as these cytokines have been implicated in the literature for their role in
perpetuating damage from IRI after kidney transplantation. Specifically, studies have
shown a significant release of IL-6 and IL-8 post-IRI by the renal allograft151 and that
blockade of these molecules can mitigate damage from IRI152. Additionally, donor
biopsies show increased expression of the genes for IL-6 and IFN post-reperfusion153.
Similarly, donor gene expression of TNF- α and IL-6 correlate with increased risk of
impaired renal function, injury and the development of chronic allograft
nephropathy154,155. Likewise, early expression of GM-CSF by tubular epithelial cells
promotes MCP-1-mediated graft fibrosis and inflammation156. Overall, these molecules
are responsible for signaling the recruitment and activation of immune cells such as
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neutrophils, macrophages, natural killer cells and T-cells into the graft, which cause
further damage to the transplanted organ and increase the risk of recognition by the
recipient’s immune system157,158. Therefore, the stimulation of pro-inflammatory cytokine
production by our model conditions is important to accurately replicate the environment
created during DCD kidney transplantation.

Importantly, our results showed that immune activity, such as cytokine expression,
was present in our model despite the absence of microbial contaminants in a sterile
environment. Cytokine production is regulated by several transcription factors, including
NF-kB, which is activated in response to signalling from pattern recognition receptors.
Pattern recognition receptors such as TLRs typically recognize microbial products known
as pathogen-associated molecular patterns (PAMPs), however, they can also be activated
by endogenous ligands from cell death and damage, known as DAMPs74. While renal
tubular epithelial cells are known to express pattern recognition receptors and participate
in the immune response during IRI75,159, we wanted to confirm TLR activation in HK-2
cells used for our model. Naïve HK-2 cells incubated with traditional TLR4 ligand, LPS,
displayed significantly increased levels of IL-6 compared to control cells, but similar
levels as seen in the IRI condition (Figure 3-9). This is consistent with previous studies
which showed increased supernatant levels of cytokines such as IL-6 and TNF- α in
response to LPS treatment160 in HK-2 cells. Therefore, we confirmed that HK-2 cells
express TLRs, and their activity is potentially triggered by our model conditions to
produce cytokines.
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To confirm that we produced TLR activity in a sterile environment, we needed to
confirm the presence of DAMPs in our model. We examined the levels of damageassociated molecular pattern, HMGB-1, which is a nuclear protein released during
necrosis-like cell death44. We observed significantly increased levels of HMGB-1 protein
in supernatants from our IRI conditions compared to untreated cells (Figure 3-7A). This
finding supports existing studies that implicate HMGB-1 as a DAMP during renal IRI
that is capable of stimulating TLRs. Specifically, HMGB-1 can activate TLR4 to produce
pro-inflammatory cytokines such as IL-6 and TNF- α after ischemia reperfusion injury
during kidney transplantation71,161,162 .

Next, to ensure the increase in cytokines levels was from innate immune activation,
we incubated fresh HK-2 cells with the DAMPs-containing conditioned media from our
sIRI conditions. We observed increased levels of pro-inflammatory cytokines IL-6, IL-8,
GM-CSF, IFN and TNF- α compared to untreated cells, but similar levels as produced in
our IRI conditions (Figure 3-11). This indicates that, mechanistically, the inflammatory
response we observe in our IRI model conditions is produced through the activation of
innate immune signaling pathways, such as TLRs. This represents an important criterion
for our model, as immune activation status during the early post-transplant period is
correlated with poor outcomes and increased risk of rejection, and is therefore an
important therapeutic target in IRI14. Overall, our model can reproduce the immune
activation and inflammatory response observed during IRI in DCD transplantation.
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Finally, our goal is to use the model to screen and study the mechanism of drugs for
their role in mitigating IRI. To support this, we showed that drugs can easily be applied in
our model and that relevant outputs, such as cell death and cytokine levels can be
monitored. Specifically, we applied pre-treatment with either Glyburide or Metformin,
clinically approved drugs that have shown promising preliminary results in mitigating
damage from IRI112,163, and measured changes in cell death parameters and cytokine
levels after IRI conditions. Neither Metformin nor Glyburide pre-treatment were able to
improve cell viability (Figure 3-12B) or apoptosis (Figure 3-12C). Additionally, cytokine
analysis indicated that pre-treatment with Metformin was able to significantly reduce
levels of IL-6, IL-8, GM-CSF compared to IRI treatment alone, while pre-treatment with
Glyburide significantly reduce IL-6, IL-8, GM-CSF, IFN and TNF- α (Figure 3-13A-E).
Interestingly, while not significant, Metformin treatment also seemed to stimulate the
production of anti-inflammatory cytokines IL-4, IL-10, and IL-13 (Figure 3-13F-H),
however further experiments are required to confirm whether this is a true effect. These
findings support the ability of our model to be used to screen and study drug candidates
for reducing IRI. Additionally, further mechanistic studies can be conducted on
promising drug candidates using this model to understand their ability to mediate damage
from IRI.

While we have shown that our model mirrors the conditions of IRI observed in
clinical DCD kidney transplantation, including key outcomes such as the induction of
hypoxia, cell death and inflammation, several limitations exist. First, and most
importantly, our model is a 2D tissue culture representation of renal IRI, which cannot
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truly encompass the complexity of IRI at the organ level. The cell microenvironment
plays a key role in how it responds to stimuli and regulates processes both in normal and
pathological conditions164. Our model does not consider important physiological aspects
such as the microfluidic environment, additional cell types present within the kidney that
respond during IRI, and loss of structural integrity which may contribute to the severity
of IRI128. Therefore, cells may behave differently in vivo than observed in our model.
However, we were able to confirm that several parameters observed during clinical IRI
were also replicated by our model, including the pro-inflammatory response. Importantly,
the ligands that activate innate immune receptors leading to inflammation have been
shown to be conserved across in vitro and in vivo studies74. Another limitation of this
study is the lack of immune cells present in our model. Infiltration of leukocytes into the
allograft, such as dendritic cells, neutrophils and macrophages are an important aspect of
tissue damage during IRI and contribute to acute rejection post-transplantation165. While
our model cannot recapitulate all in vivo elements of IRI, we selected tubular epithelial
cells, which express cytokines in a sterile environment through activation of TLRs159, and
share mechanistic aspects of IRI pathogenesis in vivo and retain susceptibility to
therapeutic intervention related to these pathways.

4.1 Future Directions and Conclusion
Therefore, despite these limitations, our model provides a unique platform to study
drug candidates and their mechanism of action in the context of renal IRI during DCD
kidney transplantation. Once further study of transcriptome and inflammasomal
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roadmaps of this model have been conducted, it will be used for large-scale drug
screening using a library of over 770 clinically approved drug candidates with predetermined dosages and concentrations. Specifically, this library will target drugs with
known anti-inflammatory, anti-TLR and anti-apoptotic effects. In addition to the
parameters considered in this study, other mechanistic analyses can be conducted for
drug candidates. For example, an NF-kB activity assay, and qPCR for expression of
TLRs, such as TLR 2,4 and 6 which have been implicated in renal IRI, would indicate the
innate immune function of drugs. Further, our model eliminates ethical concerns and
financial constraints associated with using animal models for large-scale drug screening.
Importantly, promising drug candidates identified using our model can be further studied
for their efficacy in vivo using our established porcine and human discard models of DCD
kidney transplantation.

In conclusion, our model provides the foundation for perfusate enhancement research
that can improve organ preservation ex vivo. The identification of a drug candidate that
can ameliorate the damage from IRI will help improve or replace current organ
preservation in static cold conditions. Additionally, repositioning of existing clinically
approved drugs will allow for the rapid translation of therapeutics to clinical use. Further,
the optimization of storage conditions will allow the opportunity to protect and repair
DCD organs. Therefore, we can increase the quality and quantity of organs available for
transplantation which can improve the quality of life of patients suffering from end-stage
renal disease.
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